Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,

Slides:

Advertisements

Similar presentations

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Advertisements

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Myocardial viability and impact of surgical ventricular reconstruction on outcomes of patients with severe left ventricular dysfunction undergoing coronary.

The Epidemic of the 20th Century: Coronary Heart Disease

Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease Ralf.

American Heart Journal

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation Anh L. Bui, MD, Maria.

Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice Manesh R.

Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Emily C. O’Brien, PhD,

Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry Sean D. Pokorney, MD, MBA,

The Effect of Smoking on the Risk of Sciatica: A Meta-analysis

Role of the CHADS2 Score in Acute Coronary Syndromes

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Laurent Macle, MD, John Cairns, MD, Kori.

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Masaya Koshizaka, MD, PhD, Renato D. Lopes, MD, PhD, MHS, L

‘Chest Pain Typicality’ in Suspected Acute Coronary Syndromes and the Impact of Clinical Experience Edward W. Carlton, MBChB, Martin Than, MBBS, Louise.

Comparative Effectiveness of Statin Therapy in Chronic Kidney Disease and Acute Myocardial Infarction: A Retrospective Cohort Study David H. Smith, PhD,

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis Islam Y. Elgendy,

Volume 14, Issue 9, Pages (September 2017)

Meta-analysis of minimally invasive coronary artery bypass versus drug-eluting stents for isolated left anterior descending coronary artery disease Ralf.

30-Day Readmissions After an Acute Kidney Injury Hospitalization

Leslie R. Harrold, MD, MPH, Daniel Peterson, MS, Ashley J

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Increased late mortality after coronary artery bypass surgery complicated by isolated new-onset atrial fibrillation: A comprehensive propensity-matched.

Todd A. Lee, PharmD, PhD, Brian Bartle, MPH, Kevin B. Weiss, MD, MPH

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Use of Targeted Temperature Management After Out-of-hospital Cardiac Arrest: A Meta- Analysis of Randomized Controlled Trials Ahmed Mahmoud, MD, Islam.

Incident Gout in Women and Association with Obesity in the Atherosclerosis Risk in Communities (ARIC) Study Janet W. Maynard, MD, MHS, Mara A. McAdams.

The Epidemic of the 20th Century: Coronary Heart Disease

Sensitive Troponin Assay and the Classification of Myocardial Infarction Anoop S.V. Shah, MD, David A. McAllister, MD, Rosamund Mills, MD, Kuan Ken Lee,

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Age and Gender Differences in Quality of Care and Outcomes for Patients with ST- segment Elevation Myocardial Infarction Sripal Bangalore, MD, MHA, Gregg.

Muhammad Amer, MD, MHS, FACP, Rehan Qayyum, MD, MHS

Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation Nasir Shariff, MD, Ravi V. Desai, MD, Kanan Patel,

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding Joanna M. Peloquin, MD, Siamak M. Seraj, MD,

The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial Daniel H. Solomon, MD, MPH, M. Elaine.

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

John P. Vavalle, MD, MHS, Renato D. Lopes, MD, PhD, Anita Y

CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban W. Frank Peacock, MD, CAPT Sally.

Myocardial viability and impact of surgical ventricular reconstruction on outcomes of patients with severe left ventricular dysfunction undergoing coronary.

Clinical Outcomes After Treatment of Cocaine-Induced Chest Pain with Beta-Blockers: A Systematic Review and Meta-Analysis Kevin Bryan Lo, MD, Hafeez.

Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study Walid Saliba, MD, MPH, Naomi.

MATCH Results: Implications for the Internist

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

Shannon M. Dunlay, MD, MS, Quinn R. Pack, MD, Randal J

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

One-way Versus Two-way Text Messaging on Improving Medication Adherence: Meta- analysis of Randomized Trials David S. Wald, MD, FRCP, Shahena Butt, MSc,

Yoko Miyasaka, MD, PhD, Marion E. Barnes, MSc, Bernard J

National Trends in Ambulatory Oral Anticoagulant Use

Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure Cherinne Arundel,

The American Journal of Medicine

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation

Acute Reperfusion Therapy in ST-Elevation Myocardial Infarction from

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Erratum Canadian Journal of Cardiology

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States Ahmet Ergin, MD, PhD, MPH, Paul.

Presentation transcript:

Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD, DaJuanicia N. Simon, MS, Laine Thomas, PhD, Jack Ansell, MD, Gregg C. Fonarow, MD, Bernard J. Gersh, MB, ChB, DPhil, Alan S. Go, MD, Elaine M. Hylek, MD, MPH, Peter Kowey, MD, Jonathan P. Piccini, MD, MHS, Daniel E. Singer, MD, Paul Chang, MD, Eric D. Peterson, MD, MPH, Kenneth W. Mahaffey, MD The American Journal of Medicine Volume 129, Issue 6, Pages 592-599.e1 (June 2016) DOI: 10.1016/j.amjmed.2015.12.026 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Flow diagram of study population according to antithrombotic therapy. CAD = coronary artery disease; DAP = dual antithrombotic therapy with 2 antiplatelet agents; OAC + AA = dual antithrombotic therapy with an oral anticoagulant plus 1 antiplatelet agent. The American Journal of Medicine 2016 129, 592-599.e1DOI: (10.1016/j.amjmed.2015.12.026) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Antithrombotic strategy by CHA2DS2-VASc score. DAP = dual antithrombotic therapy with 2 antiplatelet agents; OAC + AA = dual antithrombotic therapy with an oral anticoagulant plus 1 antiplatelet agent; TT = triple antithrombotic therapy (oral anticoagulation plus dual antiplatelet therapy). The American Journal of Medicine 2016 129, 592-599.e1DOI: (10.1016/j.amjmed.2015.12.026) Copyright © 2016 The Authors Terms and Conditions

Figure 3 Antithrombotic strategy by ATRIA bleeding score. ATRIA = Anticoagulation and Risk Factors in Atrial Fibrillation; DAP = dual antithrombotic therapy with 2 antiplatelet agents; OAC + AA = dual antithrombotic therapy with an oral anticoagulant plus 1 antiplatelet agent; TT = triple anti-throm-botic therapy (oral anticoagulation plus dual antiplatelet therapy). The American Journal of Medicine 2016 129, 592-599.e1DOI: (10.1016/j.amjmed.2015.12.026) Copyright © 2016 The Authors Terms and Conditions

Figure 4 1-year outcomes. CI = confidence interval; CNS = central nervous system; DAP = dual antithrombotic therapy with 2 antiplatelet agents; HR = hazard ratio; MI = myocardial infarction; OAC + AA = dual antithrombotic therapy with an oral anticoagulant plus 1 antiplatelet agent; TIA = transient ischemic attack; TT = triple antithrombotic therapy (oral anticoagulation plus dual antiplatelet therapy). The American Journal of Medicine 2016 129, 592-599.e1DOI: (10.1016/j.amjmed.2015.12.026) Copyright © 2016 The Authors Terms and Conditions

Figure 5 Cumulative incidence plot showing all-cause hospitalization at 1 year. DAP = dual antithrombotic therapy with 2 antiplatelet agents; OAC + AA = dual antithrombotic therapy with an oral anticoagulant plus 1 antiplatelet agent; TT = triple antithrombotic therapy (oral anticoagulation plus dual antiplatelet therapy). The American Journal of Medicine 2016 129, 592-599.e1DOI: (10.1016/j.amjmed.2015.12.026) Copyright © 2016 The Authors Terms and Conditions

Supplementary Figure Antithrombotic strategy by CHADS2 score. DAP = dual antithrombotic therapy with 2 antiplatelet agents; OAC + AA = dual antithrombotic therapy with an oral anticoagulant plus 1 antiplatelet agent; TT = triple anti-throm-botic therapy (oral anticoagulation plus dual antiplatelet therapy). The American Journal of Medicine 2016 129, 592-599.e1DOI: (10.1016/j.amjmed.2015.12.026) Copyright © 2016 The Authors Terms and Conditions